Polycystic Ovary Syndrome
Conditions
Interventions
Patients with the Polycystic Ovarian Syndrome (48 patients) will be randomly divided into two groups.
The experimental group with 24 patients will receive metformin 500mg, 3 tablets at night during 60
Drug
Sponsors
Hospital das Clínicas da Universidade Federal de Minas Gerais
Hospital das Clínicas da Universidade Federal de Minas Gerais
Eligibility
Sex/Gender
Female
Age
15 Years to 50 Years
Inclusion criteria
Inclusion criteria: Premenopausal women diagnosed with polycystic ovary syndrome using the Rotterdam criteria (2003)
Exclusion criteria
Exclusion criteria: Use of antiandrogen medication in the last six months or hormones, including hormonal contraceptives, or metformin in the last two months. Obesity grade II or higher, defined as body mass index greater than 35 kg / m2. Pregnancy, postpartum and lactation. Diabetes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in serum irisin levels and brown fat tissue volume after eight weeks of use of metformin or placebo in relation to pre-intervention values. The methods used to assess outcomes will be enzyme immunoassay (for serum irisin) and positron-emission tomography (brown adipose tissue). | — |
Secondary
| Measure | Time frame |
|---|---|
| Improved metabolic profile and reduced body weight after eight weeks of use of metformin or placebo from pre and post intervention or observation period | — |
Countries
Brazil
Contacts
Public ContactFernando Reis
Hospital das Clínicas da Universidade Federal de Minas Gerais
Outcome results
None listed